AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.590

+0.1601.29%

Volume:1.20M

Turnover:15.06M

Market Cap:1.60B

PE:11.59

High:12.730

Open:12.600

Low:12.265

Close:12.430

Loading ...

Overview Company News Filings

Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low

MT Newswires Live

Why these top ASX 200 growth shares could rise 35%+ in 2025

Invest $10,000 into these ASX 200 shares in January

Declining Stock and Solid Fundamentals: Is The Market Wrong About Neuren Pharmaceuticals Limited (ASX:NEU)?

Simply Wall St.

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

Invest $5,000 into these ASX 200 shares in 2025

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

There's more to Australian biotech than just CSL: the opportunities to watch

NewMarket Sets New $500 Million Share Buyback Plan

MT Newswires Live

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

Neuren Pharmaceuticals Says Partner Acadia Completes Sale of Rare Pediatric Disease Priority Review Voucher

MT Newswires Live

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

How your 20 most-tipped ASX stocks performed in 2024

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu

THOMSON REUTERS

Buy Hold Sell: 5 dogs of 2024 tipped to rebound in 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.59,"timestamp":1741237920000,"preClose":12.43,"halted":0,"volume":1198634,"delay":0,"changeRate":0.012872,"change":0.16,"floatShares":110014206,"shares":127012624,"eps":1.086099,"lyrEps":1.111713,"pbRate":4.39,"amount":15058600,"amplitude":0.037409,"volumeRatio":1.4671859567185537,"dividePrice":0,"prevYearClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":110014206,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":1.4671859567185537,"shares":127012624,"dividePrice":0,"high":12.73,"amplitude":0.037409,"preClose":12.43,"low":12.265,"week52Low":10.9,"pbRate":"4.39","psRate":"7.37","week52High":24,"institutionHeld":0,"latestPrice":12.59,"eps":1.086099,"divideRate":0,"volume":1198634,"delay":0,"ttmEps":1.086099,"open":12.6,"prevYearClose":12.5,"prevWeekClose":13.23,"prevMonthClose":13.23,"prevQuarterClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93,"sixtyDayClose":12.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503679634","title":"Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2503679634","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503679634?lang=en_us&edition=fundamental","pubTime":"2025-01-15 08:41","pubTimestamp":1736901677,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals'  partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.The application is expected to be approved in the first quarter of 2026, the filing said.Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2503254561","title":"Why these top ASX 200 growth shares could rise 35%+ in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503254561","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503254561?lang=en_us&edition=fundamental","pubTime":"2025-01-14 09:30","pubTimestamp":1736818200,"startTime":"0","endTime":"0","summary":"] Digital Realty recently reported a record sales quarter during which it sold double the data centre capacity of its previous high and about four times more capacity than it usually sells in a quarter. This reinforces our view that the significant demand for cloud computing and AI-related digital infrastructure is going to unpin attractive returns and long-term growth. […] Our preferred exposure is NEXTDC. It has 17 operational data centres in Australia and nearly a dozen under construction or about to be built across Australasia and Asia.  Morgans currently has an add rating and $20.50 price target on its sha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/14/why-these-asx-200-growth-shares-could-rise-35-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NXT.AU","BK7503","BK7043","BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2501144245","title":"Invest $10,000 into these ASX 200 shares in January","url":"https://stock-news.laohu8.com/highlight/detail?id=2501144245","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501144245?lang=en_us&edition=fundamental","pubTime":"2025-01-06 05:25","pubTimestamp":1736112325,"startTime":"0","endTime":"0","summary":"Do you have $10,000 to invest into ASX 200 shares in January?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/06/invest-10000-into-these-asx-200-shares-in-january/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2237438978.USD","IE00BSNM7G36.USD","LU1791807156.HKD","BK7104","LU2237443978.SGD","BK7096","IE00BFXG1179.USD","BK7503","BK4504","BK4550","BK4516","BK4552","LU1668664300.SGD","IE0004091025.USD","BK4588","TAM.AU","XRO.AU","BK7016","IE0034235188.USD","LU2237443895.HKD","BK4585","LU2237443382.USD","LU2237443549.SGD","LU2237443622.USD","IE00B19Z3B42.SGD","BK7508","BK4533","LU2237443465.HKD","NEU.AU","IE0004086264.USD","BK4127","IE00B19Z3581.USD","LU0106831901.USD","IE0002270589.USD"],"gpt_icon":1},{"id":"2494595016","title":"Declining Stock and Solid Fundamentals: Is The Market Wrong About Neuren Pharmaceuticals Limited (ASX:NEU)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2494595016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494595016?lang=en_us&edition=fundamental","pubTime":"2024-12-25 09:43","pubTimestamp":1735091005,"startTime":"0","endTime":"0","summary":"With its stock down 12% over the past three months, it is easy to disregard Neuren Pharmaceuticals (ASX:NEU). However...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/declining-stock-and-solid-fundamentals-is-the-market-wrong-a-1444","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK7096","NEU","BK4109","BK7508"],"gpt_icon":1},{"id":"2492391510","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2492391510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492391510?lang=en_us&edition=fundamental","pubTime":"2024-12-18 05:51","pubTimestamp":1734472274,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUE5ZBLKN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2492254766","title":"Invest $5,000 into these ASX 200 shares in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492254766","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492254766?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:41","pubTimestamp":1734385260,"startTime":"0","endTime":"0","summary":"If you are fortunate enough to have $5,000 spare to invest into ASX 200 shares, then read on. That's because listed below are three shares that analysts are tipping as top buys for the year ahead. Her","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/17/invest-5000-into-these-asx-200-shares-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00BSNM7G36.USD","LU2237443622.USD","BK7508","BK7505","LU2237443549.SGD","BK4127","BK4585","BK4504","BK7137","LU2237443382.USD","BK4516","LU2237438978.USD","IE00BFXG1179.USD","BK4552","IE0002270589.USD","IE0034235188.USD","LU0106831901.USD","LU2237443978.SGD","LU2237443895.HKD","BK4588","LU1668664300.SGD","BK4550","IE0004091025.USD","IE00B19Z3581.USD","NEU.AU","IE0004086264.USD","DMP.AU","BK7097","TWE.AU","IE00B19Z3B42.SGD","LU2237443465.HKD","LU1791807156.HKD","BK7096","BK4533"],"gpt_icon":0},{"id":"2491018345","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2491018345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491018345?lang=en_us&edition=fundamental","pubTime":"2024-12-16 06:13","pubTimestamp":1734300824,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241215:nTUE2CXFCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["CSL","BK7501","NEU.AU","CVB.AU","SNT.AU","BK7511","BK4086","LU0728928796.USD","BK7096","OPT.AU","CSL.AU","LU1169589451.USD","BK7508","XAO.AU","BK7502","XJO.AU","DXB.AU","TLX.AU","BOT.AU","LU1169590202.USD","IMM.AU","BK7007","BK7067","SGXZ23171101.USD","SG9999004303.SGD","XKO.AU"],"gpt_icon":0},{"id":"2491363592","title":"NewMarket Sets New $500 Million Share Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2491363592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491363592?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:35","pubTimestamp":1734042953,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) said late Thursday it received board approval for a new share repurchase program for up to $500 million of its common stock.The new program runs until Dec. 31, 2027, and replaces the c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4109","BK7096","BK7508","NEU","NEU.AU"],"gpt_icon":0},{"id":"2491357057","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2491357057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491357057?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:55","pubTimestamp":1734040525,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUE6BCHYJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2490479817","title":"Neuren Pharmaceuticals Says Partner Acadia Completes Sale of Rare Pediatric Disease Priority Review Voucher","url":"https://stock-news.laohu8.com/highlight/detail?id=2490479817","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490479817?lang=en_us&edition=fundamental","pubTime":"2024-12-12 08:07","pubTimestamp":1733962077,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its Nasdaq-listed partner Acadia Pharmaceuticals completed the sale of a rare pediatric disease priority review voucher for $150 million, according to a Thursday filing with the Australian bourse.The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.The company is entitled to one-third of the proceeds under its license agreement with Acadia, according to the filing.Price : $13.42, Change: $-0.02, Percent Change: -0.15%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426417589.USD","BK4125","LU2238339852.HKD","AKR","LU0426412945.USD","LU0345774631.USD","NEU.AU","BK7096","BK4231","LU0994945656.USD","LU1043141123.HKD","BK4080","AUD","BK7508"],"gpt_icon":0},{"id":"2490027051","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2490027051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490027051?lang=en_us&edition=fundamental","pubTime":"2024-12-11 06:35","pubTimestamp":1733870145,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUE2SHH3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2490162024","title":"How your 20 most-tipped ASX stocks performed in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490162024","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490162024?lang=en_us&edition=fundamental","pubTime":"2024-12-11 06:30","pubTimestamp":1733869803,"startTime":"0","endTime":"0","summary":"2024 has been a remarkable period for Australian investors, defying expectations and setting new benchmarks. The S&P/ASX 200 achieved seven monthly record closes  – the most since 2007 – while Commonwealth Bank soared well beyond analyst predictions, trading comfortably above $150 despite consensus target prices around $90. Meanwhile, tech stocks such as Wisetech, Life360, and Technology One reached unprecedented heights.At the start of the year, almost 5,000 Livewire and Market Index readers participated in the Outlook Series Survey, and  we identified your 20 top-tipped ASX stocks. As with any forecast, the results were a mixed bag – some picks flourished while others floundered. Yet, the survey provides fascinating insights into market expectations and actual performance.Please note: We are sharing information from the Livewire and Market Index readerships by publishing this list. We hope it inspires ideas for your investment research. This information is not, nor is it intended to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/how-your-20-most-tipped-asx-stocks-performed-in-2024","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/how-your-20-most-tipped-asx-stocks-performed-in-2024","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["CSL.AU","BK7103","PME.AU","BK7007","BK7096","BK7508","NEU.AU","RMD.AU","BK7501","BK7067","BK7511","SIG.AU","TLX.AU","BK7094"],"gpt_icon":0},{"id":"2490308960","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2490308960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490308960?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:12","pubTimestamp":1733782339,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUE3Z0WLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2490875799","title":"Neuren Pharmaceuticals Ltd-Update - Notification of Buy-Back - Neu","url":"https://stock-news.laohu8.com/highlight/detail?id=2490875799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490875799?lang=en_us&edition=fundamental","pubTime":"2024-12-09 05:36","pubTimestamp":1733693795,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUE660MFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2489491958","title":"Buy Hold Sell: 5 dogs of 2024 tipped to rebound in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2489491958","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489491958?lang=en_us&edition=fundamental","pubTime":"2024-12-06 04:00","pubTimestamp":1733428823,"startTime":"0","endTime":"0","summary":"The end of the year naturally brings a time of reflection. We collectively get a moment to breathe and reflect on our family, friends, and careers.For those who play Mr. Market's game, we also invariably run a critical eye over our portfolios and make some decisions on what to keep and what to turf out like four-day-old Christmas leftovers.Shedding the duds also means hunting for new opportunities and while piling into the top 10 best performers from this year is always tempting, there are probably some equal, if not better opportunities to be had in the downtrodden.With that in mind, this latest episode of Buy Hold Sell sees Henry Jennings from Marcus Today and Hugh Dive from Atlas Funds Management rummaging through the equity bargain bin like someone who camps out for the Boxing Day sales. Will they find any unloved gems?As a bonus, Henry and Hugh each nominate a stock they think is set to get going in 2025.Note: This episode was recorded on Wednesday 4 December 2024. You can watch t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/buy-hold-sell-5-dogs-of-2024-tipped-to-rebound-in-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/buy-hold-sell-5-dogs-of-2024-tipped-to-rebound-in-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7509","BK7507","BK7070","BUY","BK7095","BK7096","BK7142","PDN.AU","BK7065","VEA.AU","NEU.AU","HOLD","MIN.AU","BUY.AU","BK7508","BK7083","WEB.AU","BK7504"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":3,"totalSize":106}]}}